P.O. Box 6447
Tromso Research Park
28 articles with Lytix Biopharma
Lytix Biopharma AS announces that LTX-315 with Adoptive Cell Therapy has been shown to generate tumor-specific T cells and stabilize the disease in patients with metastatic soft tissue sarcoma (STS).
Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma.
Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022
Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces that an abstract relating to LTX-315 in combination with Adoptive Cell Therapy has been selected for presentation at a Poster Session during American Society of Clinical Oncology 2022.
The CMD is a live event, open for physical attendance at Hotel Continental in Oslo, Norway, as well as a live webcast.
Lytix Biopharma is pleased to announce that it will host a Capital Markets Day for investors, analysts and media on Wednesday, June 1, 2022
Lytix Biopharma AS (Lytix), a clinical-stage company with an in situ vaccination technology platform targeting cancer indications, today announces that its abstract has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 3-7, 2022.
Lytix Biopharma receives milestone payment from Verrica Pharmaceuticals Inc. triggered by first patient dosed with LTX-315
Lytix Biopharma AS notes that the first patient has been dosed in Verrica Pharmaceuticals Inc.'s Phase II study evaluating LTX-315 for the treatment of basal cell carcinoma (skin cancer).
5/28/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
8/13/2020Biopharma and life sciences companies from across the globe provide updates on their business and pipelines.
11/14/2019Companies from across the globe provide updates on their business and pipelines.
Lytix Biopharma announces a clinical collaboration agreement with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
Lytix Biopharma AS announces a clinical collaboration with the US-based company Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte technology, to evaluate Lytix`s first-in-class oncolytic peptide, LTX-315, in combination with Iovance`s autologous ready to infuse T cell therapy.
9/20/2019Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week's appointments.
6/14/2019Biotech and pharma companies strengthen their leadership teams and boards with new hires and appointments.
Lytix Biopharma AS Announces the Addition of Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma From the MD Anderson Cancer Center to its SAB and as Company Strategic Advisors
Dr James Allison is Regental Professor and Chair of Immunology and Executive Director of Immunotherapy at the MD Anderson Cancer Clinic, University of Texas.
Lytix Biopharma and KAEL–GemVax Announce First Patient Treated in Clinical Trial to Combine LTX-315 and GV1001 Cancer Vaccine Immunotherapy
Lytix Biopharma Announces Approval by Hungarian Authorities and Ethics Committee to Start Phase IIa Clinical Trial with LytixarTM (LTX-109) in Gram Positive Skin Infections
Lytix Biopharma and KAEL–GemVax announce approval of joint clinical trial to combine LTX-315 and GV1001 cancer vaccine immunotherapy
Lytix Biopharma Announces Regulatory Approval by Swedish Authorities to Commence Phase I/IIa Clinical Trial with LytixarTM (LTX-109) in MRSA